Cencora Boosts Earnings with OneOncology Acquisition, Raises Full-Year Guidance
Event summary
- Cencora's Q2 2026 revenue rose 3.8% YoY to $78.4B, with GAAP EPS at $8.40 and adjusted EPS up 7.5% to $4.75.
- The acquisition of OneOncology contributed to a $1.1B remeasurement gain and increased operating expenses by 20.9% YoY.
- Full-year adjusted EPS guidance raised from $17.45-$17.75 to $17.65-$17.90, reflecting strong U.S. Healthcare Solutions performance.
- International Healthcare Solutions revenue grew 13% YoY, driven by European distribution growth.
- Cencora announced plans to merge MWI Animal Health with Covetrus and acquire EyeSouth Partners’ retina business.
The big picture
Cencora's strategic focus on acquisitions and international expansion reflects broader industry trends toward consolidation and specialization in healthcare services. The company's ability to manage integration costs and leverage its expanded portfolio will be critical in maintaining its position as a Fortune 100 healthcare solutions provider. The raised guidance signals confidence in long-term value creation, but execution risks remain.
What we're watching
- Integration Challenges
- The pace at which Cencora can integrate OneOncology and realize synergies will impact future profitability.
- Debt Management
- Whether Cencora can sustain its debt paydown and share repurchase strategy amid rising interest expenses.
- Market Dynamics
- How GLP-1 sales growth and manufacturer price declines will affect U.S. Healthcare Solutions margins.
Related topics